| US 7,601,505 B2 | ||
| Compositions, kits, and methods for identification, assessment, prevention, and therapy of breast cancer | ||
| John E. Monahan, Walpole, Mass. (US); Sebastian Hoersch, Arlington, Mass. (US); Dustin L. Anderson, Brighton, Mass. (US); Wilson O. Endege, Norwood, Mass. (US); Donna Ford, Plainville, Mass. (US); Karen Glatt, Natick, Mass. (US); Bella O. Gorbatcheva, Boston, Mass. (US); Shubhangi Kamatkar, Newton, Mass. (US); Yong Yao Xu, Belmont, Mass. (US); Manjula Gannavarapu, Acton, Mass. (US); Xumei Zhao, Wayland, Mass. (US); Robert Schlegel, Auburndale, Mass. (US); Maureen Mertens, Stow, Mass. (US); Robert C. Bast, Jr., Houston, Tex. (US); Gabriel N. Hortobagyi, Bellaire, Tex. (US); and Lajos Pusztai, Pearland, Tex. (US) | ||
| Assigned to Millennium Pharmaceuticals, Inc., Cambridge, Mass. (US); and Board of Regents, The University of Texas Systems, Austin, Tex. (US) | ||
| Filed on May 26, 2004, as Appl. No. 10/855,588. | ||
| Claims priority of provisional application 60/474281, filed on May 29, 2003. | ||
| Claims priority of provisional application 60/555557, filed on Mar. 23, 2004. | ||
| Prior Publication US 2005/0042642 A1, Feb. 24, 2005 | ||
| Int. Cl. G01N 33/53 (2006.01); C12Q 1/70 (2006.01) | ||
| U.S. Cl. 435—7.1 [435/5] | 24 Claims |
| 1. A method for predicting the clinical outcome of a breast cancer patient, the method comprising:
a) determining the level of expression of marker M708 in a patient sample, wherein the M708 marker is selected from the group
consisting of a marker that is at least 95% identical to the entire sequence of SEQ ID NO:75 or a marker that is at least
95% identical to the entire sequence of SEQ ID NO:76;
b) determining the level of expression of marker M708 in a sample from a control subject having a good clinical outcome; and
c) comparing the level of expression of marker M708 in the patient sample and in the sample from the control subject;
wherein a higher level of expression of marker M708 in the patient sample as compared to the expression level in the sample
from the control subject predicts that the patient will have a poor clinical outcome.
|